Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EFIR .025 x .03 .03's printing!!!
EFIR .03's print .025 x .03
EFIR .03's print up 11%
TSNP Signs LOI for a Reverse Merger With InPlays Sports Corp.
Marketwire "Press Releases"
NEW CANAAN, CT -- (MARKET WIRE) -- 09/08/11 --
Tesoro Enterprises Inc (PINKSHEETS: TSNP) today announced that it has signed a non-binding letter of intent (LOI) which contemplates a proposed reverse merger with InPlays Sports Corp. (InPlays), a privately held company specializing in online media and marketing targeting high school and college students.
Under the terms of the LOI, InPlays would acquire Tesoro Enterprises Inc., pursuant to the contemplated merger exchange agreement. Following the closing of the anticipated merger, InPlays would emerge as the surviving company with a name and symbol change to follow. The merger is subject to a number of conditions, including the signing of a definitive merger agreement by November 7, 2011.
Commenting on the potential merger, InPlays CEO Andrew Barwicki stated: "After significantly growing our business over the past few years, I strongly believe that the next logical step in our corporate development is having our stock quoted in a public market. The greater access to capital and overall visibility afforded by operating as a publicly-traded organization should play an instrumental role in our ability to expand both through acquisition and the organic growth of our existing business."
Mr. Barwicki concluded, "My due diligence to date reveals strong evidence that a potential reverse merger with Tesoro represents a solid opportunity to take the InPlays business model to the next level. I look forward to updating the public on our progress with regard to pursuing this agreement in the very near future."
Tesoro CEO Bud Boucher added, "I believe that a merger with InPlays Sports Corp is the best option for our company. Upon a definitive merger agreement being signed, the Fashion Floor Covering and Tile Inc. stores will be spun off into a private company."
TSNP .0002 Reverse Merger News
EFIR set up to run on Thin Lv2
EFIR UT to .026, Get-R-Done!!!
$$$EFIR$$$ AWESOME NEWS & Thin to .04 IMHO
$$$EFIR$$$ Thin to .04c IMHO
$$$EFIR$$$ Thin with Great News!!!
EFIR with Great news and very VERY Thin IMHO
EFRI could move nicely with more awareness!!!
BOCX now 122%
BOCX up 108% on AWESOME News!!! ;) I told ya'll BOCX!!!
BOCX up 105% on AWESOME News!!!
BOCX .035's print up 94%
EFIR Joint Venture News!!! (OTCBB: EFIR) announced the execution of a Letter of Intent for the purpose of establishing a Joint Venture Partnership (the JVP) between EGPI Firecreek, Inc. and Paradigm Oil and Gas, Inc. (OTCBB: PDGO) (Paradigm).
EFIR with News!!!
EFIR & BOCX Running on News!!
EFIR & BOCX Monster plays today!!!
EFIR News very nice!!! up 14% and thin!!!
EFIR News Out and AWESOME Run with PDGO following suite as well!!!
EFIR Moving nicely up 14%
BOCX up 72%
BOCX up 72% on Awesome News!!!
BOCX to hit .10 on this news IMHO
BOCX News Here and stock up 66% BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
In a study to be presented at the ISOBM (International Society of Oncology and Biomarkers) annual meeting in October, BioCurex compared the performance of RECAF and free-PSA to discriminate prostate cancer from benign prostate hyperplasia (BPH), a common benign condition that requires no surgical treatment. The RECAF test outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.
Men over 50 years of age are screened with PSA (Prostate Specific Antigen) for prostate cancer. PSA is secreted by the prostate but it is not specific for cancer and therefore benign prostate conditions also show elevated PSA. As a result, two thirds of prostate biopsies are cancer negative and are not necessary.
A prostate biopsy is obtained by inserting 6-12 needles into the prostate. The most common procedure is carried out from the rectum following an enema and antibiotic coverage, using ultrasound for guidance. Discomfort, bleeding and infection are the most common complications. Thus, it is important to minimize the number of unnecessary biopsies while still detecting the highest possible number of cancer cases.
To reduce unwanted biopsies, the "free-PSA" test was developed and approved by the FDA. PSA circulates "free" as well as attached to other proteins. In the 1990's, the percentage of free-PSA was shown to be somehow lower in cancer patients than in patients with benign conditions. Unfortunately, the number of unnecessary biopsies prevented by the free-PSA test is only 11-28% as shown in the approved FDA applications from large diagnostic companies.
The BioCurex study was done using blinded samples from two different sources and showed that FDA approved free-PSA tests would have reduced unnecessary biopsies by 11%, whereas the RECAF test, used on the same samples, would have reduced the number of unwanted biopsies by approximately 70% while detecting a comparable percentage of cancers.
The potential commercial impact of these results is very significant, because this is a very specific application for which there is a pressing need and which is not currently addressed in an adequate fashion.
The standard PSA blood test costs between $20 and $60. The free-PSA blood test costs about $100. Medicare and most health insurers typically cover PSA tests for men over 50. It is estimated that in the USA alone - which represents 5% of the worldwide population - over 1.5 million men are eligible for a free-PSA test and therefore also for a RECAF test.
BOCX News IS AWESOME!!!
BOCX test eliminates 70% of Biopsies requirements!!!
BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
In a study to be presented at the ISOBM (International Society of Oncology and Biomarkers) annual meeting in October, BioCurex compared the performance of RECAF and free-PSA to discriminate prostate cancer from benign prostate hyperplasia (BPH), a common benign condition that requires no surgical treatment. The RECAF test outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.
Men over 50 years of age are screened with PSA (Prostate Specific Antigen) for prostate cancer. PSA is secreted by the prostate but it is not specific for cancer and therefore benign prostate conditions also show elevated PSA. As a result, two thirds of prostate biopsies are cancer negative and are not necessary.
A prostate biopsy is obtained by inserting 6-12 needles into the prostate. The most common procedure is carried out from the rectum following an enema and antibiotic coverage, using ultrasound for guidance. Discomfort, bleeding and infection are the most common complications. Thus, it is important to minimize the number of unnecessary biopsies while still detecting the highest possible number of cancer cases.
To reduce unwanted biopsies, the "free-PSA" test was developed and approved by the FDA. PSA circulates "free" as well as attached to other proteins. In the 1990's, the percentage of free-PSA was shown to be somehow lower in cancer patients than in patients with benign conditions. Unfortunately, the number of unnecessary biopsies prevented by the free-PSA test is only 11-28% as shown in the approved FDA applications from large diagnostic companies.
The BioCurex study was done using blinded samples from two different sources and showed that FDA approved free-PSA tests would have reduced unnecessary biopsies by 11%, whereas the RECAF test, used on the same samples, would have reduced the number of unwanted biopsies by approximately 70% while detecting a comparable percentage of cancers.
The potential commercial impact of these results is very significant, because this is a very specific application for which there is a pressing need and which is not currently addressed in an adequate fashion.
The standard PSA blood test costs between $20 and $60. The free-PSA blood test costs about $100. Medicare and most health insurers typically cover PSA tests for men over 50. It is estimated that in the USA alone - which represents 5% of the worldwide population - over 1.5 million men are eligible for a free-PSA test and therefore also for a RECAF test.
BOCX News runnin up 66%
BOCX running on this news!!! up 66%
BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
In a study to be presented at the ISOBM (International Society of Oncology and Biomarkers) annual meeting in October, BioCurex compared the performance of RECAF and free-PSA to discriminate prostate cancer from benign prostate hyperplasia (BPH), a common benign condition that requires no surgical treatment. The RECAF test outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.
Men over 50 years of age are screened with PSA (Prostate Specific Antigen) for prostate cancer. PSA is secreted by the prostate but it is not specific for cancer and therefore benign prostate conditions also show elevated PSA. As a result, two thirds of prostate biopsies are cancer negative and are not necessary.
A prostate biopsy is obtained by inserting 6-12 needles into the prostate. The most common procedure is carried out from the rectum following an enema and antibiotic coverage, using ultrasound for guidance. Discomfort, bleeding and infection are the most common complications. Thus, it is important to minimize the number of unnecessary biopsies while still detecting the highest possible number of cancer cases.
To reduce unwanted biopsies, the "free-PSA" test was developed and approved by the FDA. PSA circulates "free" as well as attached to other proteins. In the 1990's, the percentage of free-PSA was shown to be somehow lower in cancer patients than in patients with benign conditions. Unfortunately, the number of unnecessary biopsies prevented by the free-PSA test is only 11-28% as shown in the approved FDA applications from large diagnostic companies.
The BioCurex study was done using blinded samples from two different sources and showed that FDA approved free-PSA tests would have reduced unnecessary biopsies by 11%, whereas the RECAF test, used on the same samples, would have reduced the number of unwanted biopsies by approximately 70% while detecting a comparable percentage of cancers.
The potential commercial impact of these results is very significant, because this is a very specific application for which there is a pressing need and which is not currently addressed in an adequate fashion.
The standard PSA blood test costs between $20 and $60. The free-PSA blood test costs about $100. Medicare and most health insurers typically cover PSA tests for men over 50. It is estimated that in the USA alone - which represents 5% of the worldwide population - over 1.5 million men are eligible for a free-PSA test and therefore also for a RECAF test.
BOCX results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
EFIR .031z print up 41.55% on expected news!!!
EFIR .031z print! up 41.5%
EFIR .031's hit!!! up 41%
EFIR .031's on deck up 37% on expected HUGE News Release Today!!!
EFIR .031's on deck with expected news today, up 37%!!!
EFIR .031's on deck up 37%